Drug developers must understand the complex bioanalytical assays for cell- and gene-therapy drug development programs and ensure that partners have the specialized expertise needed for complex therapeutic classes.
Jenifer Vija
Advertisement
Jenifer Vija is scientific director, bioanalysis, at Charles River Laboratories.
Articles by Jenifer Vija
Advertisement
Latest Updated Articles
Emerging Therapies Test Existing Bioanalytical MethodsFebruary 1st 2019
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CPHI Pharma Award Winner: Drug Delivery, Devices, & Packaging
2
France Remains One of Europe’s Leading Biotech Funding Hubs
3
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
4
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
5